Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension

被引：0
|
作者：
Lucas M. Kimmig
Chuanhong Liao
Remzi Bag
机构：
[1] The University of Chicago Medicine,Section of Pulmonary and Critical Care Medicine
[2] The University of Chicago,Department of Public Health Sciences
[3] The University of Chicago,Biological Sciences Division
来源：
Lung | 2020年 / 198卷
关键词：
Pulmonary arterial hypertension; Prostacyclins; Prostanoids; Inhaled prostanoids; Transition;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：53 / 58
页数：5
相关论文
共 50 条
  • [41] Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension
    Olsson, Karen M.
    Richter, Manuel J.
    Kamp, Jan C.
    Gall, Henning
    Heine, Alexander
    Ghofrani, Hossein-Ardeshir
    Fuge, Jan
    Ewert, Ralf
    Hoeper, Marius M.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (07) : 748 - 756
  • [42] Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension
    Vachiéry, JL
    Hill, N
    Zwicke, D
    Barst, R
    Blackburn, S
    Naeije, R
    CHEST, 2002, 121 (05) : 1561 - 1565
  • [43] Prostanoid therapies in the management of pulmonary arterial hypertension
    Le Varge, Barbara L.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 535 - 547
  • [44] Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension
    Hopper, Rachel K.
    Ivy, D. Dunbar
    Yung, Delphine
    Mullen, Mary P.
    Hanna, Brian D.
    Kirkpatrick, Edward
    Hirsch, Russel
    Austin, Eric D.
    Fineman, Jeffrey
    Solum, Derek
    Deng, C. Q.
    Feinstein, Jeffrey A.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2020, 76 (01) : 94 - 100
  • [45] Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil
    Ascha, Mona
    Zhou, Xuan
    Rao, Youlan
    Minai, Omar A.
    Tonelli, Adriano R.
    CARDIOVASCULAR THERAPEUTICS, 2017, 35 (05)
  • [46] Long-term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension
    Tamura, Yuichi
    Furukawa, Asuka
    Tamura, Yudai
    Yamada, Kenta
    Taniguchi, Hirohisa
    Fukuda, Keiichi
    Kawamura, Akio
    Satoh, Toru
    PULMONARY CIRCULATION, 2022, 12 (01)
  • [47] Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referral
    Badagliacca, Roberto
    Pezzuto, Beatrice
    Poscia, Roberto
    Mancone, Massimo
    Papa, Silvia
    Marcon, Serena
    Valli, Gabriele
    Sardella, Gennaro
    Ferrante, Fabio
    Iacoboni, Carlo
    Parola, Daniela
    Fedele, Francesco
    Vizza, Carmine Dario
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (04) : 364 - 372
  • [48] Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
    Mirza, Shireen
    Foley, Raymond J.
    CLINICAL MEDICINE INSIGHTS-CIRCULATORY RESPIRATORY AND PULMONARY MEDICINE, 2012, 6 : 41 - 50
  • [49] A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension
    Coons, James C.
    Crisamore, Karryn
    Adams, Solomon
    Modany, Ashley
    Simon, Marc A.
    Zhao, Wenchen
    Shaik, Imam H.
    Venkataramanan, Raman
    Empey, Philip E.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2021, 15
  • [50] Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date
    Cassady, Steven J.
    Almario, Jose Alejandro N.
    Ramani, Gautam, V
    DRUG HEALTHCARE AND PATIENT SAFETY, 2024, 16 : 51 - 59
12345